Result of GM and Update on Issue of Equity
IXICO plc announced that all resolutions were passed at its General Meeting concerning the Placings, Subscription, and Retail Offer, authorizing directors to allot relevant securities for cash up to an aggregate nominal amount of £1,312,500 for the fundraising and an additional £746,395 under a general authority, with Resolution 1 passing with 78.67% of votes for. The company is still awaiting Advanced Assurance from HM Revenue & Customs for the equity issue, which is a condition for the First and Second Admissions, initially expected on April 17 and April 20, 2026, respectively, with long stop dates of May 17 and May 19, 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the Placings, Subscription and Retail Offer, as announced by the Company on 31 March 2026, were duly passed.
| Resolution | For | Against | Total | Withheld | ||||
|---|---|---|---|---|---|---|---|---|
| Number of votes | % | Number of votes | % | Number of votes | % | Number of votes | ||
| 1 | To authorise the Directors to allot relevant securities for cash up to an aggregate nominal amount of £1,312,500 in connection with the Fundraising and a further £746,395 pursuant to an ongoing general authority | 47,575,433 | 78.67% | 12,895,688 | 21.33% | 60,471,121 | 65.26 | 10,829 |
| 2 | To authorise the Directors of the Group to adopt the Non-Employee Sub-Plan to the IXICO Share Option Plan | 46,575,493 | 77.02% | 13,900,162 | 22.98% | 60,475,655 | 65.26 | 6,295 |
| 3 | To authorise the Directors to issue and allot equity securities on a non-pre-emptive basis up to a maximum aggregate nominal amount of £1,312,500 for cash on a non-pre-emptive basis in connection with the Fundraising and a further £223,918 pursuant to an ongoing general authority | 47,550,738 | 78.63% | 12,924,915 | 21.37% | 60,475,653 | 65.26 | 6,297 |
- A vote Withheld is not a vote in law and is not counted in the calculation of the votes cast For or Against the resolution, nor in the calculation of the percentage of issued share capital voted for any resolution.
- Votes For and Against are expressed as a percentage of votes validly cast for that resolution by proxy, excluding any Withheld votes.
Update on Issue of Equity and Advanced Assurance
As announced in the 'Placings and Subscription' RNS dated 31 March 2026, the First Placing and Subscription are conditional, amongst other things, on (a) the passing of certain shareholder resolutions at a General Meeting; and (b) receipt of Advanced Assurance from HM Revenue & Customs issued under the Income Tax Act 2007; and (c) admission of the New Ordinary Shares to trading on AIM, initially expected to be 17 April 2026 in respect of First Admission and 20 April 2026 in respect of Second Admission. As of the date of this announcement, the Company has not yet received Advance Assurance from HM Revenue & Customs but expects to do so shortly. The Company will make a further announcement in due course to advise the market of the revised timetable for both the First Admission and the Second Admission, together with confirmation of the Company's total voting rights. The Company notes that the First Admission Long Stop Date is 17 May 2026 and the Second Admission Long Stop Date is 19 May 2026.
Capitalised terms used in this announcement have the meaning given to them in the announcement dated 31 March 2026, unless otherwise defined in this announcement.
Giles Balleny, Isaac Hooper, Andrea Callaghan (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.